<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02300129</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.40225E</org_study_id>
    <nct_id>NCT02300129</nct_id>
  </id_info>
  <brief_title>Effect of CD07805/47 Gel in Rosacea Flushing</brief_title>
  <official_title>Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of
      the flush of rosacea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study in rosacea patients (type I&amp;II) are:

        -  to demonstrate objectively that CD07805/47 0.5% gel is able to prevent a flush induced
           by a specific trigger (hot water) in controlled condition;

        -  to demonstrate that CD07805/47 0.5% gel is able to prevent a flush whatever the trigger
           in everyday life condition;

        -  to investigate if reduction in redness is associated with a decrease in skin sensations
           such as heat, stinging/burning, skin tension and sweating;

        -  to demonstrate that such efficacy on transient redness and sensations takes place in
           both populations (rosacea type I and rosacea type II).

      This is a single-centre, randomized, Investigator masked, placebo controlled study comprising
      the following periods:

      A screening period of maximum 4 weeks

      A one-week treatment phase (Period 1) with 3 sessions using the flush model, every other day.

      This Period 1 includes a cross-over design (first and third sessions) and a split face design
      (second session). During this period, thirty six (36) subjects will receive on site the study
      drugs as follows (the order of each session being randomized):

        -  CD07805/47 placebo gel on both sides of the face,

        -  one side of the face treated with CD07805/47 0.5% gel, the other side treated with the
           CD07805/47 placebo gel (the allocation of treatment on each half-face will be determined
           according to a randomization list),

        -  CD07805/47 0.5% gel on both sides of the face;

      A 2-days wash-out period (between Period 1 and Period 2) with no treatment on either side of
      the face

      A 4-week treatment phase (Period 2) corresponding to a cross-over design during which the
      subjects will apply themselves the study drugs at home on the whole face, once daily 7 days
      per week.

      The subjects will be divided in 2 groups of eighteen (18) subjects and will receive either
      the CD07805/47 0.5% gel the first 2 weeks and then the CD07805/47 placebo gel or the
      CD07805/47 placebo gel the first 2 weeks and then the CD07805/47 0.5% gel, according to
      randomization.

      All the subjects taking part into the study will not be randomized separately in the two
      periods but to the full sequence at the beginning of the clinical trial (same randomization
      number during all the study), explaining the arms/groups detailed in the section &quot;Arms and
      Interventions&quot;.

      Only primary efficacy endpoint: total number of flushes for each 2-week period will be
      detailed in the outcome measures section.

      The other endpoints are secondary or exploratory.

      The purpose of Period 1 is to assess whether simpler and shorter designs based on flush
      induced by a trigger could be as efficient to detect prevention of flush than the more
      classical and longer design of Period 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Flushes for Each 2-week Period</measure>
    <time_frame>Day 22 and Day 36/Early termination</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)
Period 2 (cross-over design):
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
Period 2 (cross-over design):
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
Period 2 (cross-over design):
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
Period 2 (cross-over design):
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</intervention_name>
    <description>Period 1:
1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.
1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</intervention_name>
    <description>Period 1:
1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.
1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</intervention_name>
    <description>Period 1:
1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of Placebo on full face once daily 7 days per week for 2 weeks.
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</intervention_name>
    <description>Period 1:
1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of Placebo on full face once daily 7 days per week for 2 weeks.
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks.</description>
    <arm_group_label>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject is a male or female, who is at least 18 years of age or older at Screening
             visit.

          2. The subject has a clinical diagnosis of mild to moderate erythemato-telangiectatic
             rosacea or mild to moderate papulo-pustular rosacea according to the National Rosacea
             Society grading (Wilkin et al., 2004)

          3. The subject had at least five flushing episodes during the last week before Screening
             and Baseline visits

        Exclusion Criteria:

          1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans,
             isolated rhinophyma, isolated pustulosis of the chin), or other concomitant facial
             dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis
             facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus or actinic
             telangiectasia;

          2. The subject has current treatment with monoamine oxidase inhibitors, barbiturates,
             opiates, sedatives, systemic anesthetics, or alpha-agonists;

          3. The subject has less than 3 months stable dose treatment with tricyclic
             anti-depressants, cardiac glycosides, beta blockers or other antihypertensive agents;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>October 20, 2015</results_first_submitted>
  <results_first_submitted_qc>August 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 20, 2016</results_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo</title>
          <description>Period 1:
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
Period 2 (cross-over design):
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo</title>
          <description>Period 1:
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
Period 2 (cross-over design):
Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
        <group group_id="P3">
          <title>CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47</title>
          <description>Period 1:
Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
Period 2 (cross-over design):
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47</title>
          <description>Period 1:
Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.
Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).
Period 2 (cross-over design):
Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 Session 1 (Day 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1 Session 2 (Day 3)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5">Withdrawal consent of 1 subject between Day 1 and Day 3</participants>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 1 Session 3 (Day 5)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 Treatment 1 (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="11">Withdrawal consent of 1 subject between the Period 1 and Period 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 Treatment 2 (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat population</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants (Intent To Treat Population)</title>
          <description>One subject was excluded from Intent to Treat (ITT) population because he didn't perform any efficacy assessment during the study so N=33 instead of 34 subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Flushes for Each 2-week Period</title>
        <time_frame>Day 22 and Day 36/Early termination</time_frame>
        <population>Per protocol population of Period 2, N= 31</population>
        <group_list>
          <group group_id="O1">
            <title>Period 2 CD07805/47 0.5% Gel Cross-over</title>
            <description>CD07805/47 0.5% gel (Brimonidine tartrate)</description>
          </group>
          <group group_id="O2">
            <title>Period 2 Placebo Gel Cross-over</title>
            <description>CD07805/47 placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Flushes for Each 2-week Period</title>
          <population>Per protocol population of Period 2, N= 31</population>
          <units>Flushes count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="12.1"/>
                    <measurement group_id="O2" value="16.3" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7420</p_value>
            <p_value_desc>P value associated to treatment effect in the model. Study design with a power of 80% and a type I error at 5% (two-sided).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Analysis of variance including sequence, subject (sequence), period and treatment as factors in the model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Period 1 Placebo Gel Cross Over</title>
          <description>Period 1 Placebo gel cross over (application on full face) Overall safety population, N=34</description>
        </group>
        <group group_id="E2">
          <title>Period 1 CD07805/47 0.5% Gel Split Face</title>
          <description>Period 1 CD07805/47 0.5% gel split face (application on one side of face) Overall safety population, N=33</description>
        </group>
        <group group_id="E3">
          <title>Period 1 Placebo Gel Split Face</title>
          <description>Period 1 Placebo gel split face (application on one side of face) Overall safety population, N=33</description>
        </group>
        <group group_id="E4">
          <title>Period 1 CD07805/47 0.5% Gel Cross-over</title>
          <description>Period 1 CD07805/47 0.5% cross over (application on full face) Overall safety population, N=33</description>
        </group>
        <group group_id="E5">
          <title>Period 2 CD07805/47 0.5% Gel Cross Over</title>
          <description>Period 2 CD07805/47 0.5% gel (application on full face) Overall safety population, N=32</description>
        </group>
        <group group_id="E6">
          <title>Period 2 Placebo Gel Cross Over</title>
          <description>Period 2 Placebo gel cross over (application on full face) Overall safety population, N=31</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <description>Cutaneous AE not related to CD07805/47 0.5 gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cheilitis</sub_title>
                <description>Cutaneous AE not related to CD07805/47 0.5 gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <description>Cutaneous AE not related to CD07805/47 0.5 gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Non cutaneous AE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Non cutaneous AE</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema and skin tightness</sub_title>
                <description>Cutaneous AE related to CD07805/47 0.5% gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Erythema, papules and pruritus</sub_title>
                <description>Cutaneous AE related to CD07805/47 placebo gel</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Erythema, papules and pruritus</sub_title>
                <description>AE of Special Interest related to CD07805/47 0.5% gel leading to subject discontinuation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Galderma CPM</name_or_title>
      <organization>Galderma R&amp;D</organization>
      <phone>00 33 4 93 95 70 70</phone>
      <email>clinicaltrials@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

